AeproMED
Hsinchu
About AeproMED
AeproMED's advanced inhalation therapy platform offers quick therapeutic onset while minimizing systemic side effects. Leveraging professional aerosol science, it ensures precise drug-aerosol delivery directly to the lungs. This versatile technology supports animal pre-clinical trials, supportive therapies, and lung disease treatment. Designed with a user-centric approach, it integrates seamlessly with respiratory medicine for chronic disease management. Additionally, it provides cutting-edge technology for developing new compounds to treat cancer or for supportive therapies in sub-health conditions. AeproMED's platform is a significant advancement in the medical and healthcare fields.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Funding stage: Seed
- Last round: Seed (Feb 2024)
- Website: aepromed.com
- Phone: +886-3-6676537
Industries & Categories
Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/aepromed-2452941 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.